![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 33, 30694-30700, August 17, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
, andFrom the Departments of Biology and Medicine, University of California, San Diego, La Jolla, California 92093-0665
Received for publication, March 29, 2001, and in revised form, May 23, 2001
| |
ABSTRACT |
|---|
|
|
|---|
The complex retroviruses such as human
immunodeficiency virus, type 1, employ a virally encoded protein, Rev,
to mediate the nuclear export of unspliced and partially spliced
mRNA. In contrast, the simian type D retroviruses act through a
cis-acting constitutive transport element (CTE) that
presumably interacts directly with cellular export proteins. We first
reported that RNA helicase A (RHA) is a shuttle protein that binds to
functional CTE in vitro and in vivo. Recently,
we isolated a novel protein, HAP95, that specifically binds to the
nuclear transport domain of RHA and up-regulates CTE-mediated gene
expression. Here, using truncation and deletion mutations, we mapped
the domains of HAP95 that are important for RHA binding,
transactivation of CTE, and nuclear cytoplasmic shuttling. We report
evidence for a novel nuclear export signal in HAP95 and showed that the
domains involved in RHA binding and nuclear localization are required
for CTE activation. Finally, we showed that HAP95 synergizes
significantly with RHA on CTE-mediated reporter gene expression and
promotes nuclear export of unspliced mRNA in transfected cells.
Taken together, these data support the proposal that HAP95 specifically
facilitates CTE-mediated gene expression by directly binding to
RHA.
Post-transcriptional regulation is an essential phase in the life
cycle of many retroviruses. A key regulatory step in this phase
involves the nuclear export of unspliced viral RNA, which requires the
interaction of viral RNA and/or proteins with cellular factors. At
least two distinct pathways have been utilized. The complex
retroviruses, such as HIV,1
encode the viral protein Rev, which acts as an adapter between the Rev
response element (RRE) on the viral RNA and the cellular export
receptor, CRM-1 (reviewed in Refs. 1 and 2). In contrast, the simian
type D retroviruses do not encode a Rev-like protein but rather act
through a cis-acting constitutive transport element (CTE).
CTE is functionally equivalent to the Rev/RRE of HIV and presumably
interacts directly with cellular export proteins to mediate the nuclear
export of unspliced viral RNA. Two cellular proteins, RNA helicase A
(RHA) and Tip-associated protein (3, 4), were shown to bind to
functional CTE and are implicated in CTE-mediated RNA nuclear export
and gene expression.
RHA was identified previously as a nuclear protein capable of unwinding
RNA duplexes in an ATP-dependent manner (5). Our laboratory
first reported that RHA binds specifically to functional CTE and is
required for CTE activity (3). We further showed that RHA is a nuclear
shuttle protein, with overlapping import and export signals localized
to the carboxyl-terminal region (6). In addition, we showed that RHA
plays a role in RRE-mediated gene expression (7). We proposed that RHA
is required to release both CTE- and RRE-containing mRNA from
spliceosomes before completion of splicing, thus freeing them for
nuclear export (6, 7). Others have reported that RHA mediates molecular
interactions between RNA polymerase II and the cAMP-response
element-binding protein-binding protein and is required for
activation of transcription in response to cAMP (8). These reports
suggest that RHA is a multifunctional protein involved in both
transcriptional and post-transcriptional events.
The nuclear export of cellular mRNA and retroviral mRNA may
proceed by a similar mechanism, facilitated by distinct specific RNA-binding proteins containing nuclear export signals (NESs). As part
of our effort to further understand the role of RHA in post-transcriptional regulation of gene expression, we searched for
functionally relevant RHA-binding proteins. A novel shuttle protein,
HAP95, was identified to interact with the nuclear transport domain of
RHA in the yeast two-hybrid assay (9). HAP95 also up-regulates CTE
function when co-expressed with a CTE reporter gene (9). HAP95 has
extensive homology with AKAP95, a member of the A-kinase anchoring
protein family (10). However, HAP95 lacks the characteristic protein
kinase A binding domain of this family.
In this report, we further characterize the different domains of HAP95
that may contribute to its activity on CTE-mediated gene expression. We
identified a novel export signal of 17 amino acids that bears no
homology with any known signal sequences, as well as two RHA-binding
regions in HAP95. We also found that the amino-terminal domain of
HAP95, including a YG-rich sequence, was essential for transactivation
of CTE, whereas a mutant truncated in the amino-terminal region exerted
a dominant negative effect. Interestingly, HAP95 synergizes with RHA on
CTE-mediated gene expression in human cells. These results broaden our
understanding of nucleo-cytoplasmic protein transport through the
identification of a new type of shuttling signal and transport pathway.
Construction of Plasmids--
The plasmids were constructed by
standard methods. For generation of FLAG-tagged mutants of HAP95, the
DNA fragments were amplified by PCR and cloned in-frame into pCMV-FLAG
vectors (Stratagene). To make expression plasmids for HAP95 and RHA
glutathione S-transferase (GST) fusion proteins, the DNA
fragments were amplified by PCR and cloned into pGEX-4T-1 vector
(Amersham Pharmacia Biotech). Plasmids GST-RHA-NTD and NPc-T NLS were
described previously (6). To create NPc-T NLS-HAP95 mutants, plasmid
pc-HAP95 was used as template in a series of PCRs. The individual
fragments were subcloned in frame into digested NPc-T NLS.
pCMV138/CTE and pSV-gagpol-MPMVCTE (gagpol-CTE) (11, 12) were described
previously. The mutant RHA (mtRHA), which lacks the helicase activity
was kindly provided by M. Montminy (Harvard Medical School, Boston,
MA). To generate the in vitro transcription plasmid
pSP72-RPA for RNA protection assay, the DNA sequence in pCMV138/CTE
that flanks the 3' splice site was PCR-amplified with primers
containing EcoRI and BglII sites and cloned into
pSP72 (Invitrogen).
Cell Culture, Transfection, and Cell Extracts--
COS-1, HeLa,
and 293T cells were grown at 37 °C in Dulbecco's modified Eagle's
medium with 10% heat-inactivated fetal bovine serum, 2 mM
glutamate, 50 units/ml penicillin, and 50 mg/ml streptomycin. The cells
were transfected by FuGeneTM 6 Transfection Reagent (Roche Molecular
Biochemicals) according to the manufacturer's recommendations. 293T
cells were transfected with various FLAG-tagged HAP95 mutant expression
plasmids. The cells were collected and lysed in lysis buffer (50 mM Tris, pH 7.5, 250 mM NaCl, 5 mM
EDTA, 0.5 mM phenylmethylsulfonyl flouride, 0.25% Nonidet
P-40, and protease inhibitors) 48 h post-transfection.
Heterokaryon Assay--
HeLa cells were transfected with
FLAG-tagged HAP95 mutants or NPc-TNLS fused HAP95 fragments expression
plasmids. The formation of heterokaryons from NIH3T3 and HeLa cells, as
well as subsequent cycloheximide treatment, cell fusion,
fixation, and staining, were done as described previously (6, 9).
CAT Assays--
293T cells were cultured in 12-well plates and
were transfected using FuGeneTM 6 transfection reagent. The reporter
plasmids containing the CAT gene along with CTE within splice donor
sites (pCMV138/CTE) were transfected. A Microscopic Examination--
HeLa cells were cultured in 4-well
chamber slides and transfected with plasmids expressing FLAG-tagged
HAP95 fusion proteins. Twenty-four hours post-transfection, the cells
were stained as described (14). Briefly, the cells were fixed for 15 min in 4% paraformaldehyde and then permeabilized by 0.5% Triton
X-100 with phosphate-buffered saline for 20 min at room temperature. They were then incubated with mouse monoclonal anti-FLAG antibody (Stratagene) for 1 h at 37 °C. After washing with
phosphate-buffered saline, the cells were incubated with fluorescein
isothiocyanate-conjugated goat anti-mouse IgG antibody for 30 min at
37 °C. The intracellular locations were examined by fluorescence microscopy.
Recombinant Proteins--
Plasmids encoding GST fusion proteins
were transformed in Escherichia coli BL21 following
induction with isopropyl- In Vitro Binding Assay--
Transfected 293T cell extracts were
incubated with GST or GST-RNA-NTD bound beads in the binding buffer A
for 2 h at 4 °C. The beads were then washed five times with
ice-cold binding buffer A. The bound GST fusion proteins were eluted by
boiling for 3 min in SDS buffer and resolved by 10% SDS-PAGE. Western
blotting was performed by a standard technique using anti-FLAG antibody (Stratagene). The protein bands were visualized by enhanced
chemiluminescence (Santa Cruz).
RNA Gel Shift Assays--
Plasmid pSP72-CTE was constructed by
inserting PCR-amplified CTE sequence into ClaI cloning site
of pSP72 (Invitrogen). [32P]UTP-labeled CTE were
synthesized by in vitro transcription with T7 RNA polymerase
according to the protocols (Promega) using EcoRI linearized
pSP72-CTE plasmid as template. RNA-protein binding reactions were
carried out at room temperature in a total volume of 15 µl of binding
buffer containing 12 mM Hepes (pH 7.9), 50 mM
NaCl, 4 mM MgCl2, 10 mM
dithiothreitol, 2 µg tRNA, 20 units of RNasin, and 10% glycerol.
Typically, 1 × 104 cpm of 32P-labeled RNA
and 150 ng of protein were used. The binding reaction was allowed to
proceed for 15 min at room temperature, and then the mixture was
electrophoresed on a 4.5% nondenaturing PAGE and visualized by autoradiography.
P24 Antigen Capture Assay--
293T cell were co-transfected
with HIV gagpol-CTE reporter plasmid pSV-gagpol-MPMVCTE, and HAP95,
RHA, and their mutant expression plasmids. Forty-eight hours
post-transfection, cell-free supernatants were collected and subjected
to p24 antigen assay (Coulter).
Co-immunoprecipitation of CTE RNA and HAP95--
293T cells were
transfected with plasmids expressing CTE RNA along with expression
plasmids for FLAG-tagged HAP95, HAP95 (268), or HAP95 (433).
Forty-eight hours post-transfection, the cells were harvested, and
co-immunoprecipitation was carried out as described before (9).
RNA Isolation and RNA Protection Assay--
COS-1 cells were
transfected with 3 µg of pcDNA3 or HAP95 or pcRHA and 2 µg of
pCMV138/CTE. Nuclear and cytoplasm RNAs were fractionated from COS-1
cell at 48 h after transfection and purified by an RNA isolation
kit (Promega). The [32P]UTP-labeled RNA probe used in
this assay was generated by in vitro transcription of
plasmid pSP72-RPA linearized at the EcoRI site, using a
Riboprob kit (Promega). The input probe is 447 nucleotides in length,
with additional tag sequence derived from vector sequence to allow the
full-length input to be distinguished from probe fragments rescued by
the unspliced and spliced mRNA transcripts, which have a predicted
length of 391 and 173 nucleotides, respectively. Ribonuclease
protection assay (RPA) analysis was performed using an RPA kit (Ambion)
following the manufacturer's protocol.
Identification of a Novel NES--
HAP95 was first identified as a
protein that binds to the nuclear transport domain of RHA in a yeast
two-hybrid screen. HAP95 is partially homologous to AKAP95, a member of
the protein kinase A anchoring protein family, but lacks the protein
kinase A-binding domain characteristic of this family. Therefore, HAP95
is by definition not a member of the AKAP family (Fig.
1). Additionally, there are several
interesting motifs in the nonhomologous regions that are unique to
HAP95. In the amino terminus, there is a region with both tandem and
nontandem repeats of a YG dipeptide sequence of unknown significance.
In the central region, there are three nucleoporin-like FG repeats, a
classical nuclear localization signal, and a bipartite nuclear
targeting motif. The carboxyl terminus is rich in acidic residues and
contains two proline-rich domains that fit the consensus for
SH3-binding domains.
Although HAP95 localizes predominantly to the nucleoplasm at steady
state, we previously showed that it continuously shuttles between the
nucleus and cytoplasm (9). To determine the domain(s) for nuclear
import and export, we carried out an interspecies heterokaryon assay
(6, 9). We made constructs expressing various deletion mutants of HAP95
tagged by a FLAG epitope at their amino termini. HeLa cells were
transfected with these expression plasmids and were fused to NIH 3T3
cells to form heterokaryons. Cycloheximide was added to inhibit
de novo protein synthesis. The mouse nuclei were
distinguished from human nuclei by their punctate staining with Hoechst
33258. As shown in Fig. 2A,
the full-length as well as all the truncated mutants of HAP95 tested, except HAP1-268, were able to shuttle from human nuclei to mouse nuclei, indicating that the NLS/NES sequences reside between amino acids 268 and 349 (Fig. 2, A and B). This segment
of HAP95 is highly hydrophobic and contains two interesting repeats
(EGTA and EEGKED) of unknown function.
To further isolate the NES, we fused various subfragments within the
amino acids 268-384 region to a construct NPc-TNLS expressing the core
domain of nucleoplasmin. SV40 large T NLS was included in these
constructs to ensure complete nuclear localization of the resultant
fusion proteins. As summarized in Fig. 2C, the fusion protein containing amino acid 268-384, but not the parental nonfusion protein, was exported from the nuclei of the transfected human cells.
The smallest fragment sufficient to maintain NES activity contains
amino acids 280-296 (Fig. 2D). Removal of five amino acid
residues from the carboxyl terminus or three residues from the amino
terminus of this region severely inactivated the NES (Fig.
2C). It should be noted that the HAP95 NLS was necessary for
complete nuclear retention of the resultant fusion proteins. When the
NLS was deleted, half of the fusion proteins containing amino acids
280-296 were found in the cytoplasm, indicating strong nuclear export
activity of the NES contained therein.
Mapping the Functional Domains of HAP95--
We previously showed
that HAP95 is a positive co-factor for CTE function. Overexpression of
HAP95 significantly increased CTE activity in transfected 293T cells
(9). To further characterize the functional domains of HAP95, we made
systematic deletion mutants of HAP95, each tagged by a FLAG epitope at
the amino terminus (Fig. 3A),
and co-transfected these with a CTE-dependent CAT reporter plasmid pCMV138/CTE into 293T cells. As shown in Fig. 3B,
introduction of full-length HAP95 resulted in about a 3-fold activation
in CTE function, consistent with our previous results. The amino terminus of HAP95 encompassing amino acids 1-384 was sufficient to
exert full transactivating function, suggesting that the zinc finger
domain and the proline-rich domain are dispensable for activity (Fig.
3B). Consistent with this, the carboxyl-terminal fragment
(amino acids 268-646) did not show any activity. Further truncation to
1-349, deleting the putative bipartite nuclear localization motif,
greatly impaired the activation. Removal of the classical NLS
completely abolished activity. To ensure that the variation in
CTE-dependent CAT activities conferred by the HAP95 mutants was not due to differences in expression level of these proteins, we
performed a Western analysis on the cell lysates. All of the HAP95
mutants were in fact expressed at comparable levels (data not shown).
These data suggest that the amino-terminal half of HAP95 is sufficient
for full CTE activation.
We also determined the subcellular distribution of the various HAP95
mutant proteins after transient transfection into HeLa cells, using
antibodies to the FLAG epitope. As shown Fig. 3C, wild-type
HAP95 was distributed within the nucleoplasmic region as well as
concentrated in punctate loci in the nucleus but was excluded from the
nucleoli. HAP95 (1) had the similar subcellular localization.
However, when the classical NLS motif was deleted, the proteins
completely localized in the cytoplasm, indicating that the bipartite
nuclear motif alone was not sufficient to counter the export activity
of the NES.
To map the minimal domain for HAP95 CTE function, we made additional
mutations within the 1-384 fragment (Fig.
4A). As shown in Fig.
4B, deletion of both FG and NES domains only slightly reduced reporter gene expression, consistent with results with either
deletion introduced into the complete HAP95 gene (data not shown). In
contrast, deletion of the YG domain in this fragment or in the context
of the complete HAP95 gene (data not shown) completely abolished
activity. Furthermore, we found that deletion of both H1 and FG domains
or of the amino-terminal 267 amino acids resulted in complete loss of
CTE activation. These results suggest that the minimal region of HAP95
for CTE activation is the amino-terminal half containing the YG, H1,
and NLS domains, whereas the FG and NES regions are dispensable.
We next measured a panel of FLAG-tagged HAP95 deletion mutants for
their interaction with RHA. The expressions of these proteins in
transfected 293T cells were confirmed to be comparable by Western blot
assay (Fig. 4C). GST and GST-RHA-NTD bound beads were
incubated with the 293T cell extracts for 2 h at 4 °C. After
extensive washing, the bound proteins were resolved on 10% SDS-PAGE
and transferred onto a nitrocellulose membrane. HAP95 mutant proteins
were identified by an anti-FLAG monoclonal antibody on a Western blot.
As shown in Fig. 4D, HAP95 and HAP 1-384 specifically bound
RHA-NTD (Fig. 4D, lanes 1-6). Pretreatment with
RNase did not affect these interactions (data not shown). HAP1-384
deleted in YG domain still bound RHA (lanes 11 and
12), whereas deletion of the H1 domain resulted in loss of
binding (lanes 9 and 10). Surprisingly, HAP95
(268) that had no activity on CTE also bound RHA NTD (lanes
15 and 16), but further truncation to 433-646
abolished the binding (lanes 17 and 18). These
data suggest that there are at least two RHA-binding regions in the
amino and carboxyl termini of HAP95, respectively, and that only the
first binding region may be involved in CTE activation.
HAP95 Does Not Bind to CTE RNA--
We previously demonstrated
that HAP95, RHA, and CTE were present in the same complex in
vivo. To further support the proposal that HAP95 mediates CTE
function through direct binding to RHA, we examined the possibility of
HAP95 directly binding to CTE RNA. Recombinant GST and GST-HAP1-384
proteins were purified from transformed E. coli and
incubated with [32P]UTP-labeled CTE RNA in binding buffer
containing an excess of yeast tRNA as a nonspecific competitor. The
reaction mixtures were then analyzed by the RNA gel mobility shift
assay on 4.5% nondenaturing polyacrylamide gels. As shown in Fig.
5, neither GST (lane 2) nor
GST-HAP1-384 (lane 3) bound to CTE RNA. In contrast, the
amino terminus (1) of RHA, containing the two double-stranded RNA-binding domains, bound to CTE RNA (Fig. 5, lanes 4-7).
Conversely, the carboxyl terminus (1014-1279) of RHA, which is
sufficient for binding to HAP95, was not able to bind to CTE RNA. These
data are consistent with the conclusion that CTE activation by HAP95 is
mediated through its direct binding with RHA.
Functional Interaction between HAP95 and RHA--
The above
results prompted us to explore the functional interaction between HAP95
and RHA in vivo. We co-transfected HAP95, RHA, or their
mutant expression plasmids with a CTE-dependent CAT
reporter plasmid and measured CAT activity at 48 h
post-transfection (Fig. 6A).
HAP95 and RHA each activated CTE-dependent CAT gene expression 3-5-fold over the control, as expected. mtRHA lacking helicase activity (8), HAP95 (268), and AKAP95 all had little or
no activation on CTE. Significantly, co-expression RHA and HAP95
synergistically increased the CAT activation to about 15-fold. This was
not seen when either HAP95 (268) or mtRHA was used. In fact, HAP95
(268) completely abolished RHA-mediated CTE function, and
conversely, mtRHA inhibited HAP95 activation of CTE, further supporting
the functional interaction of RHA and HAP95.
Similar results were obtained with a second CTE reporter system,
i.e. pSV-gagpol-MPMVCTE (11). Co-transfecting RHA or HAP95 with the reporter plasmid resulted in a 14- and 16-fold increase in gag
expression as measured by p24 antigen capture assay, respectively (Fig.
6B). Again, RHA and HAP95 together exerted a synergistic effect, resulting in a 600-fold increase in p24 gag expression above
the basal level. The HAP95 (268) mutant again had little effect on
p24 gag expression on its own and significantly inhibited RHA
activation in this assay.
To address whether the dominant negative effect of the HAP95
(268) is through blocking the complex formation between RHA and CTE or forming a nonproductive ternary complex, we carried out an
in vivo co-immunoprecipitation assay. 293T cells were
transfected with plasmid expressing CTE RNA, along with plasmids
expressing FLAG-tagged HAP95, HAP95 (268), HAP95 (433), or
pFLAG vector. The tagged proteins were immunoprecipitated by anti-FLAG
antibodies, and the presence of CTE was verified by reverse
transcription-PCR with CTE-specific primers (9). As shown in Fig.
6C, CTE RNA co-immunoprecipitated with both HAP95 and HAP95
(268). These results suggest that HAP95 (268) was still able
to form a ternary complex with CTE RNA in vivo, presumably
through interaction with RHA.
HAP95 Increases CTE-dependent Nuclear RNA
Export--
To explore the underlying mechanism of HAP95 and RHA on
CTE-mediated gene expression, we conducted an RNase protection assay using RNA prepared from COS-1 cells transfected with pCMV138/CTE in the
presence or the absence of co-expressed HAP95 or RHA. The indicator
plasmid pCMV138/CTE encodes a cat reporter gene that is
downstream of a functional CTE located between 5' and 3' splice sites
(Fig. 7A). Total RNA from the
nuclear and cytoplasmic fractions of COS-1 cells were isolated 48 h post-transfection, and intracellular RNA distributions were measured
by RNase protection assays. As shown in Fig. 7B (lanes
3 and 4), the unspliced mRNA was detected mainly in
the nucleus. However, overexpression of HAP95 or RHA dramatically
increased the unspliced reporter mRNA species (lanes 6 and 8) in the cytoplasm but had no effect on the relative
levels of spliced and unspliced RNA in the nuclear fraction. These
results support the proposal that both RHA and HAP95 facilitated the
nuclear export of unspliced, CTE-containing mRNA in human
cells.
The Rev protein of HIV-1 promotes the nuclear export of
RRE-containing mRNA by directly binding to the export receptor
hCRM1 through its NES (15-17). Rev function is inhibited by the
antibiotic leptomycin B, which disrupts the interaction of hCRM1 and
RanGTP, thus abolishing the export of the NES-containing proteins. The CTE of type D retroviruses, in contrast, functions independently of
hCRM1 and is therefore insensitive to leptomycin B. This latter export
pathway appears to be shared by most cellular mRNAs. Our laboratory
has shown that RHA not only binds to CTE but also plays a critical role
in mediating the nuclear export of CTE-containing mRNA (7). The
shuttling function of RHA was not affected by leptomycin B (6). In
searching for proteins that bind specifically to the NTD of RHA, we
identified HAP95, which also up-regulates CTE-mediated gene expression
(9). In this work, we have extended this earlier study by mapping the
functional domains of HAP95 and providing strong evidence for a direct
role of HAP95 in RHA-mediated nuclear export of CTE-containing mRNA.
HAP95 also shuttles between the nucleus and the cytoplasm. We
identified a strong NES with 17 amino acids localized between a
classical basic NLS and a bipartite NLS in HAP95 (Fig. 1). This NES has
no similarity to known signals for nuclear export, including the
leucine-rich NES found in Rev and the bi-directional transport signals
found in hnRNP A1, hnRNP K, and RHA (6, 18, 19). Consistent with this,
the HAP95 NES could not rescue the function of an NES-defective Rev
mutant (data not shown). Interestingly, we found that the NES signal in
HAP95 was neither necessary nor sufficient for its activation of
CTE-mediated gene expression (Fig. 3B). In fact, deletion of
NES resulted in a greater than 2-fold increase in activation over
full-length HAP95. It is possible that the NES of RHA and HAP95 compete
for a subset of cellular factors even though they may have different
conditions for nucleo-cytoplasmic trafficking. This is evidenced by the
fact that with actinomycin D treatment, RHA distributes to the
cytoplasm, whereas HAP95 stays in the nucleus (data not shown).
Nonetheless, further investigation on the HAP95 NES may reveal a new
pathway of nuclear export for other proteins containing a similar
NES.
We have mapped the minimal functional domains of HAP95 to its
amino-terminal half of the protein. The critical regions include a
YG-clustered region at the amino terminus, the first AKAP95 homology
domain (H1), and the classical NLS (Fig. 3B). Deletion of
the bipartiite NLS significantly impaired but did not abolish CTE
activation. Of these regions, the H1 domain appears to be required for
binding of the functional subfragment HAP95 (1) to RHA (Fig.
4B), and NLS is required for nuclear localization of the
protein (Fig. 3C). Deletion of the YG domain both in
full-length and (1) of HAP95 completely abolished their CTE
activation function (Figs. 3B and 4B), without
affecting their ability to shuttle or to bind RHA. Therefore, the role
of this domain remains to be determined. It is intriguing to note that
these YG repeats are not found in AKAP95 (Fig. 1). Despite extensive
BLAST searches, we could not find similar YG repeats in other proteins.
Taking together, the amino terminus of HAP95 is responsible for its
activation of the CTE-mediated gene expression pathway.
The results with the H1 deletion strongly suggest that HAP95 activation
of CTE requires the directly binding of RHA (Fig. 4). This conclusion
was further supported by the observation that HAP95 (1), which was
fully active, did not bind to CTE RNA (Figs. 3B and 5).
Furthermore, HAP95 and RHA interaction is independent of RNA
(RNase-resistant). However, the most convincing and most striking
evidence for the functional interaction of HAP95 and RHA was their
dramatic synergy on activation of CTE-mediated gene expression in
vivo (Fig. 6, A and B). This synergy was
specific because AKAP95, which has extensive homology with HAP95, had
no such effect. An RHA mutant lacking helicase activity also failed to
act on its own or to synergize with HAP95 in activating
CTE-dependent gene expression.
We also directly demonstrated that both RHA and HAP95 promote an
increase in cytoplasmic accumulation of CTE-containing RNA, using an
RNase protection assay (Fig. 7). Because HAP95 does not directly bind
CTE and its NES is not required for this effect, its exact mechanism of
action is not known. We hypothesized that this effect is mediated
through its direct interaction with RHA. Currently, a number of
cellular proteins have been implicated in CTE-mediated gene expression.
In addition to RHA and HAP95, Tap was shown to bind CTE and mediate CTE
function in quail cells (20, 21). We recently reported that Sam68,
which activates basal as well as Rev-mediated RRE- gene expression,
also significantly activated gene expression of a CTE-gag/pol construct
(13, 22). We further showed that RHA functionally interacts with Tap
and Sam68 (22). Based on these and other results, we proposed that Sam68, RHA, and Tap cooperate in the post-transcriptional regulation of
HIV and type D retroviral mRNA. Recently, an NTF2-like protein, p15, was found to bind to Tap and to enhance the binding of Tap to CTE
(23). One can expect that additional factors relevant to this
regulatory pathway will still be discovered and that these various
cellular factors may contribute to the function of CTE and RRE at
various steps between RNA transcription and nuclear export. These may
include splicing, mRNA stability, polyadenylation, and nuclear
retention. Additional insights into these processes should be gained as
the network of interacting proteins and RNA is elucidated.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-galactosidase expression
plasmid was used as an internal control of transfection efficiency.
pcDNA3 was used to equalize the amount of DNA for each
transfection. The cell extracts were prepared 48 h
post-transfection and tested for CAT activity through standard assay
procedures as described previously (13).
-D-thiogalactoside. Recombinant
GST fusion proteins were purified by incubating the bacterial extracts
in buffer A (50 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl flouride, 0.25% Nonidet P-40, and
protease inhibitors) with glutathione-Sepharose beads (Amersham
Pharmacia Biotech). The beads were then pelleted, washed five times
with ice-cold buffer A, and suspended in 1 ml of buffer A. GST and GST
fusion proteins for RNA gel shift were eluted with buffer containing 20 mM glutathione. The purity of GST fusion proteins were
examined by 10% SDS-polyacrylamide gel electrophoresis (PAGE)
and stained using Coomassie Brilliant Blue. The quantity of proteins
was measured by the DC protein assay (Bio-Rad).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (14K):
[in a new window]
Fig. 1.
Schematic illustration of various domains of
HAP95 and AKAP95. YG-rich region, FG repeat, putative NLS and
bi-partitis NLS, proline-rich regions, and the two zinc finger domains
are indicated. The two regions of homology to AKAP95 are located in the
amino and carboxyl termini, respectively. The binding domain to the
regulatory subunit of protein kinase A in AKAP95 is indicated.

View larger version (51K):
[in a new window]
Fig. 2.
Mapping the nuclear export signal of
HAP95. A, HeLa cells were transfected with expression
vectors encoding the FLAG-tagged HAP95 mutants. After expression of the
transfected DNAs, the cells were fused with NIH3T3 cells to form
heterokayons and incubated in the medium containing 100 µg/ml
cycloheximide for a period of 1 h. The cells were then
fixed and stained for immunofluorescence microscopy with FLAG antibody
to localize the proteins, and Hoechst 33258 (middle column),
which differentiates the human and mouse nuclei within the
heterokaryon. The arrows identify the mouse nuclei.
B, summary of results depicted in A. C, definition of the minimal NES sequence. Expression
vectors encoding the indicated NPc fusion proteins were transfected
into HeLa cells. The heterokaryon assay was carried out as described in
A. The immunofluorescence staining was carried out with mAb
9E10 antibody. A summary of the results is shown. D, the
minimally defined nuclear export domain.

View larger version (35K):
[in a new window]
Fig. 3.
Mapping the functional domains of HAP95.
A, schematic illustration of variouse mutants of HAP95.
B, various HAP95 mutants on the CTE-dependent
activation. 293T cells were co-transfected with pCMV138/CAT 150 ng and
various HAP95 mutants (300 ng) expression plasmids. Forty-eight hours
post-transfection, the cell extracts were prepared, and the CAT enzyme
assay was carried out as described previously. C,
subcellular localization of various HAP95 mutants. HeLa cells were
transiently transfected with expression vectors encoding various
FLAG-tagged HAP95 mutants. Twenty-four hours post-transfection, the
cells were fixed and stained with an FLAG antibody. The fluorescence
was visualized by fluorescence microscopy.

View larger version (32K):
[in a new window]
Fig. 4.
Binding to RHA is required for HAP95
function. A, schematic illustration of variouse mutants
of HAP95. B, various HAP95 mutants on the
CTE-dependent activation. 293T cells were transfected with
the indicated plasmids. The CAT enzyme assay was carried out as
described in Fig. 3. C, expression of various
FLAG-tagged HAP95 mutants. HeLa cells were transfected with various
HAP95 mutants expression plasmids. The expression of various
FLAG-tagged HAP95 mutants are confirmed by a Western blot assay.
D, various HAP95 mutants binding to GST-RHA-NTD. The cell
extracts were incubated with matrix-bound GST or GST-RHA-NTD for
binding assay. The bound proteins were resolved by 10% SDS-PAGE and
subjected for Western blot assay. The protein bands were recognized by
anti-FLAG antibody.

View larger version (82K):
[in a new window]
Fig. 5.
HAP95 does not bind to CTE RNA in
vitro. GST and GST fusion proteins were purified from
expression bacteria. Approximately 150 ng of the indicated proteins
were incubated with 32P-labeled RNA in binding buffer at
room temperature for 15 min. The reaction mixture was detected by a
4.5% nondenaturing polyacrylamide gel electrophoresis followed by
autoradiography. The positions of the free RNA probe and of the
protein-RNA complex are indicated on the right.
NC, negative control.

View larger version (28K):
[in a new window]
Fig. 6.
HAP95 synergies with RHA in CTE-directed
reporter gene expression. A, activation of CTE-directed
CAT expression. 293T cells were transfected with the indicated
combinations of plasmids (o.6 µg) and the reporter plasmid
pCMV138/CAT (0.3 µg). Forty-eight hours post-transfection, the cell
extracts were prepared and subjected to CAT enzyme assays as described
under "Experimental Procedures." B, activation of
CTE-directed gag expression. 293T cells were co-transfected gagpol-CTE
(0.5 µg) and various expression plasmids (0.5 µg). The expression
level of p24 gag was measured 48 h post transfection by p24
antigen capture assay. C, interaction of HAP95 and CTE RNA.
Reverse transcription (RT)-PCR-amplified RNA samples from
cells expressing CTE RNA co-immunoprecipitated with HAP95 or HAP95
(268). The control reactions with plasmid DNA containing the CTE
are shown. Reverse transcription-PCR was carried out with reverse
transcriptase/Taq polymerase mix (+) or with Taq
polymerase alone (
).

View larger version (69K):
[in a new window]
Fig. 7.
HAP95 increases CTE-dependent
nuclear RNA export. A, structures of the plasmid
construct. The solid boxes and the thin lines
denote the exon and the intron sequences from the HIV-1 gene,
respectively. The CTE sequence and the HIV-1 polyadenylation sequence
are also marked. The probe and the predicted protected bands are
indicated. 5'ss, 5' splice site; 3'ss, 3' splice
site; nt, nucleotides. B, levels of expression of
the spliced (S) or unspliced (U) RNA encoded by
pCMV138/CTE in the nucleus (N) or cytoplasm (C)
were determined using RNase protection analysis in COS-1 cells
co-transfected pCMV138/CTE with the indicated plasmids. Lanes
1 and 2, yeast RNA as control (Con.) without
or with RNase. Ten micrograms of RNA was used in each lane.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank Ky Thanh Truong for technical assistance and Kimberly Roberts for critical review of the manuscript. We also acknowledge the Center for AIDS Research (which was supported by National Institutes of Health Grant P30AI 36214) and Dr. James Feramisco of the University of California, San Diego, Cancer Center for providing core facilities for microscopic studies.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant GM056089 (to F. W.-S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Present address: Wayne State University, School of Medicine,
Detroit, MI 48201.
§ To whom correspondence should be addressed: Stein Clinical Research Bldg., University of California, San Diego, La Jolla, CA 92093-0665. Tel.: 858-534-7957; Fax: 858-534-7743; E-mail: fwongstaal@ucsd.edu.
Published, JBC Papers in Press, June 11, 2001, DOI 10.1074/jbc.M102809200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: HIV, human immunodeficiency virus; RRE, Rev response element; CTE, constitutive transport element; RHA, RNA helicase A; NES, nuclear export signal; PCR, polymerase chain reaction; GST, glutathione S-transferase; CAT, chloramphenicol acetyltransferase; PAGE, polyacrylamide gel electrophoresis; NTD, nuclear transport domain; RPA, ribonuclease protection assay; mtRHA, mutant RHA.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Hope, T. J. (1999) Arch. Biochem. Biophys. 365, 186-191 |
| 2. | Pollard, V. W., and Malim, M. H. (1998) Annu. Rev. Micro. 52, 491-532 |
| 3. | Tang, H., Gaietta, G. M., Fischer, W. H., Ellisman, M. H., and Wong-Staal, F. (1997) Science 276, 1412-1415 |
| 4. | Gruter, P., Tabernero, C., von Kobbe, C., Schmitt, C., Saavedra, C., Bachi, A., Wilm, M., Felber, B. K., and Izaurralde, E. (1998) Mol. Cell 1, 649-659 |
| 5. | Zhang, S., and Grosse, F. (1991) J. Biol. Chem. 266, 20483-20490 |
| 6. | Tang, H., McDonald, D., Middlesworth, T., Hope, T., and Wong-Staal, F. (1999) Mol. Cell. Biol. 19, 3540-3550 |
| 7. | Li, J., Tang, H., Mullen, T., Westberg, C., Reddy, T. R., Rose, D. W., and Wong-Staal, F. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 709-714 |
| 8. | Nakajima, T., Uchida, C., Anderson, S. F., Lee, C. G., Hurwitz, J., Parvin, J. D., and Montminy, M. (1997) Cell 90, 1107-1112 |
| 9. | Westberg, C., Yang, J.-P., Tang, H., Reddy, T. R, and Wong-Staal, F. (2000) J. Biol. Chem. 275, 21396-21401 |
| 10. | Coghlan, V. M., Langeberg, L. K., Fernandez, A., Lamb, N. J., and Scott, J. D. (1994) J. Biol. Chem. 269, 7658-7665 |
| 11. | Bray, M., Prasad, S., Dubay, J. W., Hunter, E., Jeang, K. T., Rekosh, D., and Hammarskjöld, M. L. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1256-1260 |
| 12. | Tang, H., Xu, Y., and Wong-Staal, F. (1997) Virology 228, 333-339 |
| 13. | Reddy, T. R., Xu, W., Mau, J. K. L., Goodwin, C. D., Suhasini, M., Tang, H., Frimpong, K., Rose, D. W., and Wong-Staal, F. (1999) Nat. Med. 5, 635-642 |
| 14. | Yang, J.-P., Hori, M., Sanda, T., and Okamoto, T. (1999) J. Biol. Chem. 274, 15662-15670 |
| 15. | Fornerod, M., Ohno, M., Yoshida, M., and Mattaj, I. W. (1997) Cell 90, 1051-1060 |
| 16. | Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., Yanagida, M., and Nishida, E. (1997) Nature 390, 308-311 |
| 17. | Ossareh-Nazari, B., Bachelerie, F., and Dargemont, C. (1997) Science 278, 141-144 |
| 18. | Michael, W. M., Choi, M., and Dreyfuss, G. (1995) Cell 83, 415-422 |
| 19. | Michael, W. M., Eder, P. S., and Dreyfuss, G. (1997) EMBO J. 16, 3587-3598 |
| 20. | Kang, Y., and Cullen, BR. (1999) Genes Dev. 13, 1126-1139 |
| 21. | Braun, I. C., Rohrbach, E., Schmitt, C., and Izaurralde, E. (1999) EMBO J. 18, 1953-1965 |
| 22. | Reddy, T. R., Tang, H., Xu, W., and Wong-Staal, F. (2000) Oncogene 19, 3570-3575 |
| 23. | Katahira, J., Straber, Podtelejnikov, A., Mann, M., Jung, J. U., and Hurt, E. (1999) EMBO J. 16, 3256-3271 |
This article has been cited by other articles:
![]() |
D. Portal, A. Rosendorff, and E. Kieff Epstein-Barr nuclear antigen leader protein coactivates transcription through interaction with histone deacetylase 4 PNAS, December 19, 2006; 103(51): 19278 - 19283. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lindtner, A. S. Zolotukhin, H. Uranishi, J. Bear, V. Kulkarni, S. Smulevitch, M. Samiotaki, G. Panayotou, B. K. Felber, and G. N. Pavlakis RNA-binding Motif Protein 15 Binds to the RNA Transport Element RTE and Provides a Direct Link to the NXF1 Export Pathway J. Biol. Chem., December 1, 2006; 281(48): 36915 - 36928. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. B. Roy, J. Hu, X. Guo, R. S. Russell, F. Guo, L. Kleiman, and C. Liang Association of RNA Helicase A with Human Immunodeficiency Virus Type 1 Particles J. Biol. Chem., May 5, 2006; 281(18): 12625 - 12635. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhong and A. R. Safa RNA Helicase A in the MEF1 Transcription Factor Complex Up-regulates the MDR1 Gene in Multidrug-resistant Cancer Cells J. Biol. Chem., April 23, 2004; 279(17): 17134 - 17141. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Zhou, K.-T. Choe, Z. Zaidi, Q. Wang, M. B. Mathews, and C.-G. Lee RNA helicase A interacts with dsDNA and topoisomerase II{alpha} Nucleic Acids Res., May 1, 2003; 31(9): 2253 - 2260. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Martins, S. Eikvar, K. Furukawa, and P. Collas HA95 and LAP2{beta} mediate a novel chromatin-nuclear envelope interaction implicated in initiation of DNA replication J. Cell Biol., January 21, 2003; 160(2): 177 - 188. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Han, Y. Xue, S. Harada, S. Orstavik, B. Skalhegg, and E. Kieff Protein Kinase A Associates with HA95 and Affects Transcriptional Coactivation by Epstein-Barr Virus Nuclear Proteins Mol. Cell. Biol., April 1, 2002; 22(7): 2136 - 2146. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zhang, K. Buder, C. Burkhardt, B. Schlott, M. Gorlach, and F. Grosse Nuclear DNA Helicase II/RNA Helicase A Binds to Filamentous Actin J. Biol. Chem., January 4, 2002; 277(1): 843 - 853. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |